title: Cell adhesion and signaling on the fibronectin 1st type III repeat; requisite roles for cell surface proteoglycans and integrins.
abstract: BACKGROUND
  The first type III repeat of fibronectin is known to be involved in fibronectin matrix assembly, and recombinant proteins from this type III repeat can inhibit cell proliferation, tumor metastasis and angiogenesis. We have analyzed the way rat aortic smooth muscle cells (RASMCs) interact with a recombinant protein encompassing a C-terminal portion of the first type III repeat of fibronectin (protein III1-C).
  
  
  RESULTS
  Cells are able to adhere to and spread on III1-C coated on a dish. Both beta1 integrins and cell surface heparan sulfate proteoglycans serve as receptors for III1-C. For example, cell attachment to III1-C is partially inhibited by agents that block beta1 integrins or by heparin. Complete inhibition of cell attachment is seen only when integrin blocking agents are combined with heparin. Affinity chromatography revealed the binding of proteins that likely represent the integrin beta1 and alpha5 submits to a III1-C column. Cell adhesion to III1-C results in robust ERK1/2 activation that is blocked by integrin-blocking agents. In addition, cell adhesion to III1-C and ERK1/2 activation by III1-C are both inhibited by heparan sulfate but not by chondroitin sulfate. Moreover, heparitinase treatment, but not chondroitinase treatment of RASMCs results in reduced cell adhesion and ERK1/2 activation. Affinity chromatography experiments demonstrated that 35SO4-labeled cell surface heparan sulfate proteoglycans bound specifically to III1-C.
  
  
  CONCLUSIONS
  The results suggest that the 1st type III repeat of fibronectin contains a previously unrecognized cell adhesion domain that stimulates robust ERK1/2 activation in RASMCs. Cells interact with this domain through cell surface heparan sulfate proteoglycans and integrins, and both classes of receptors are required for optimal cell adhesion and ERK1/2 activation.
authors.affiliation: Department of Pathology, MC 1089 Committee on Cancer Biology, University of Chicago, S Maryland Ave, Chicago, IL, USA. kmercuri@midway.uchicago.edu
authors.forename: K O
authors.initials: KO
authors.lastname: Mercurius
authors.forename: A O
authors.initials: AO
authors.lastname: Morla
mesh_terms: D000818:Animals; D002448:Cell Adhesion; D002478:Cells, Cultured; D005353:Fibronectins / Q000737:chemistry* / Q000235:genetics / Q000502:physiology*; D019812:Heparan Sulfate Proteoglycans / Q000502:physiology*; D019012:Integrin beta1 / Q000502:physiology*; D020935:MAP Kinase Signaling System; D008562:Membrane Glycoproteins / Q000502:physiology*; D020928:Mitogen-Activated Protein Kinases / Q000378:metabolism; D009131:Muscle, Smooth, Vascular / Q000187:drug effects / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000494:pharmacology; D020449:Repetitive Sequences, Amino Acid
chemical_list: D005353:Fibronectins; D019812:Heparan Sulfate Proteoglycans; D019012:Integrin beta1; D008562:Membrane Glycoproteins; D011994:Recombinant Proteins; D020928:Mitogen-Activated Protein Kinases